1. Academic Validation
  2. Discovery of ACH-000143: A Novel Potent and Peripherally Preferred Melatonin Receptor Agonist that Reduces Liver Triglycerides and Steatosis in Diet-Induced Obese Rats

Discovery of ACH-000143: A Novel Potent and Peripherally Preferred Melatonin Receptor Agonist that Reduces Liver Triglycerides and Steatosis in Diet-Induced Obese Rats

  • J Med Chem. 2021 Feb 25;64(4):1904-1929. doi: 10.1021/acs.jmedchem.0c00627.
Marcos Antonio Ferreira Jr 1 Hatylas Azevedo 1 Alessandra Mascarello 1 Natanael Dante Segretti 1 Elisa Russo 2 Valter Russo 2 Cristiano Ruch Werneck Guimarães 1
Affiliations

Affiliations

  • 1 Aché Laboratórios Farmacêuticos, Guarulhos, São Paulo 07034-904, Brazil.
  • 2 Zirkon Ind. Com de Insumos Químicos, Itapira, São Paulo 13977-105, Brazil.
Abstract

The modulation of melatonin signaling in peripheral tissues holds promise for treating metabolic diseases like obesity, diabetes, and nonalcoholic steatohepatitis. Here, several benzimidazole derivatives have been identified as novel agonists of the melatonin receptors MT1 and MT2. The lead compounds 10b, 15a, and 19a demonstrated subnanomolar potency at MT1/MT2 receptors, high oral bioavailability in rodents, peripherally preferred exposure, and excellent selectivity in a broad panel of targets. Two-month oral administration of 10b in high-fat diet rats led to a reduction in body weight gain similar to dapagliflozin with superior results on hepatic steatosis and triglyceride levels. An early toxicological assessment indicated that 10b (also codified as ACH-000143) was devoid of hERG binding, genotoxicity, and behavioral alterations at doses up to 100 mg/kg p.o., supporting further investigation of this compound as a drug candidate.

Figures
Products